Visit the ACCC COVID-19 Resource Center & Discussion Group for Insights on Providing Optimal Patient Care During the Pandemic.



In This Section

Home / Learn / Resource Detail

Integrating Biosimilars Within a Community, Academic, or Health-System Setting

May 9, 2019

While an increasing number of biosimilar agents have been approved in recent years, there remains among providers a general lack of familiarity about them that poses a significant barrier to their widespread adoption.

Pharmacy leaders have an important role to play in introducing biosimilars to oncology care and determining how and where they can be substituted for reference products to contribute to healthcare savings. Biosimilars have the potential to reduce costs and increase value, not only by lowering the price of medications, but also by decreasing patient out-of-pocket costs. To ensure the effective integration of biosimilars into clinical practice, public awareness about their potential benefits; the collection of real-world data on safety and efficacy; and collaboration among clinicians, health economists, and policymakers must increase.

Related Content